arlutz73
Bristol Myers Squibb (NYSE:BMY) said a Phase 3 study for its drug Zeposia in the treatment of moderate-to-severe active Crohn’s disease failed to meet its primary endpoint of clinical remission at week 12.
The study was the first of two 12-week induction studies for the YELLOWSTONE Phase 3 clinical trial. The drugmaker didn’t mention the status of the second study in its statement.
Zeposia, also known as ozanimod, is already approved by the FDA for the treatment of multiple sclerosis and ulcerative colitis.
More on Bristol-Myers Squibb Company
- Bristol-Myers Squibb Is Not A Buy For Me
- Bristol-Myers Squibb Company (BMY) Barclays 26th Annual Global Healthcare Conference (Transcript)
- Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Partners Global Biopharma Conference 2024 Conference (Transcript)
- China's Xi Jinping plans to meet with U.S. CEOs in China next week - report
- Bristol Myers gets EU approval for Abecma for multiple myeloma